New Research Poster Presentation 2.16
Are Emerging Treatments in Fragile X Syndrome Relevant to Autism Spectrum Disorder?
Thursday, October 24, 2013
Jeremy Veenstra-VanderWeele, MD, Psychiatry, Pediatrics, and Pharmacology, Vanderbilt University, Nashville, TN
Linmarie Sikich, MD, The University of North Carolina at Chapel Hill, Chapel Hill, NC
Raun Melmed, MD, Melmed Center, Scottsdale, AZ
Jana von Hehn, PhD, Seaside Therapeutics, Inc., Cambridge, MA
Karen Walton-Brown, U.S. Renal Care, Plano, TX
Maryann Cherubini, Seaside Therapeutics, Inc., Cambridge, MA
Peter Zarevics, Seaside Therapeutics, Inc., Cambridge, MA
Randall Carpenter, Seaside Therapeutics, Inc., Cambridge, MA
Mark Bear, PhD, Seaside Therapeutics, Inc., Cambridge, MA
Paul Wang, MD, Seaside Therapeutics, Inc., Cambridge, MA
Edwin H. Cook Jr., MD, University of Illinois, Chicago, IL
